Pfizer Inc. Stock
€21.87
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.280% | -1.801% | 2.636% | -14.708% | 2.467% | -45.893% | -26.285% |
| Johnson & Johnson | 0.240% | 2.118% | 7.688% | 30.831% | 7.469% | 22.716% | 41.388% |
| Biogen Inc. | -0.780% | -0.473% | -2.029% | 6.164% | -1.735% | -44.881% | -36.762% |
| Elanco Animal Health Inc. | -0.020% | -4.599% | 5.120% | 71.398% | 4.652% | 56.347% | -15.483% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
3 High-Yield Stocks to Buy Hand Over Fist in January
The S&P 500 index offers a paltry 1.1% dividend yield. By that standard, even consumer products giant Procter & Gamble's (NYSE: PG) 2.8% yield looks lofty. Here's why dividend lovers may want to
This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years
It's been a miserable past three years for Pfizer (NYSE: PFE) shareholders. Although this drugmaker's stock was all the rage in the early days of the COVID-19 pandemic, as it co-created a
The Best Stocks to Invest $40 in to Start the New Year Off Right
Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) underperformed in 2025. Both companies encountered some issues, some of which may linger throughout this year.
However, these drugmakers